Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

October 17, 2022

1 minute read

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

Lennox International Says On Nov 28, Max Mitchell, President, CEO Of Crane Co., Notified Co Of His Decision To Resign From Board, Effective Immediately

December 2, 9:46 AM

-SEC Filing

October 3, 3:06 PM

Piper Sandler analyst Crispin Love reiterated a Neutral rating on SEI Investments Company (NASDAQ: SEIC),

January 12, 3:06 PM

A look at the top 10 bestselling electric vehicles in the United States in 2023, which includes brands from Tesla, GM and Ford.

July 18, 1:04 PM

Analysts have provided the following ratings for Ameren (NYSE:AEE) within the last quarter: